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RESUMO  
A síndroma de Rett (RTT) é uma doença de causa genética que origina 
disfunção cognitiva severa, epilepsia, atraso no desenvolvimento, perda da 
funcionalidade das mãos, desenvolvimento de movimentos estereotipados das mãos e 
dificuldades de interacção social. A RTT é causada, principalmente, por mutações no 
gene MeCP2 presente no cromossoma X. Em RTT, a sinalização do factor neurotrófico 
derivado do cérebro (BDNF) está comprometida. O BDNF regula a sobrevivência 
neuronal, diferenciação e plasticidade sináptica como a Potenciação a Longo Prazo, 
aceita como a base neurofisiológica de aprendizagem e memória. O aumento da 
sinalização de BDNF seria um avanço importante, mas tem sido dificultado devido à 
dificuldade de administrar BDNF no Sistema Nervoso Central. Por outro lado, 
Adenosina é um neuromodelador que actua principalmente via receptor A1 e A2A 
através de acções inibitórias e excitatórias, respectivamente, que tem sido apontado 
como agente antiepiléptico devido ao seu papel neuroprotector. A activação do 
receptor A2A potencia as acções sinápticas do BDNF em animais saudáveis. Deste 
modo, a exploração quer da facilitação das acções do BDNF resultantes da activação de 
receptores A2A quer dos efeitos inibitórios benéficos provocados por agonistas dos 
receptores A1 vistos em modelos de epilepsia, seria uma abordagem terapêutica 
interessante em RTT. Animais MeCP2 Knockout (KO) (B6.129P2 (C) -Mecp2tm1.1Bird/J) 
foram usados para a caracterização dos receptores A1 e A2A quer funcional quer 
molecularmente. Verificámos que o sistema adenosinérgico está comprometido no 
modelo RTT com a possível redução dos níveis de adenosina e consequente diminuição 
do tónus adenosinérgico inibitório via A1R que, deste modo, contribui para a 
susceptibilidade epiléptica em RTT. Os nossos resultados favorecem a um aumento de 
expressão dos receptores A2A e embora a quantificação proteica não revelar a mesma 
tendência. Em conclusão, aumentando a actividade mediada pelo receptor A1 seria 
possível prevenir a excitabilidade patológica e susceptibilidade epiléptica. Por outro 
lado, a activação dos receptores A2A poderia evitar disrupção das acções do BDNF e 
exercer potencial papel benéfico na cognição. 
Palavras-Chave: Síndroma de Rett, Adenosina, receptor A1, receptor A2A, BDNF. 
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ABSTRACT  
Rett syndrome (RTT) is the main cause of intellectual disability in females, 
causing severe cognitive dysfunction, epilepsy, stereotypical movement of the hands, 
and it is triggered mainly by mutations in the X-linked MeCP2 gene. In RTT, brain-
derived neurotrophic factor (BDNF) signaling is impaired. BDNF regulates neuronal 
survival, differentiation and synaptic plasticity such as long-term potentiation (LTP), 
accepted as the neurophysiological basis for learning and memory. The increase of 
BDNF signaling would be a significant breakthrough, but has been hampered by the 
difficulty to administer BDNF to the central nervous system. On the other hand, 
Adenosine is a neuromodulator that acts mainly through A1 and A2A receptors through 
inhibitory and excitatory actions, respectively, and has been pointed as antiepileptic 
due to its neuroprotective role. The activation of A2AR potentiates BDNF synaptic 
actions in healthy animals. Therefore, the exploration of whether the activation of 
A2AR facilitates BDNF action simultaneously with the inhibitory benefits of agonists of 
A1R seen in epilepsy models could be an interesting therapeutic approach in RTT. 
MeCP2 Knockout (KO) (B6.129P2 (C)-Mecp2tm1.1Bird/J) animals were used for 
molecular and functional characterization of A1 and A2A receptors. We found that 
adenosinergic system is compromised in the RTT model with a possible reduction on 
adenosine levels and a consequent decrease of inhibitory adenosinergic tonus via A1R 
contributing for the epileptic susceptibility in RTT. Our results favor an increase in A2AR 
mRNA expression. In conclusion, the increase in A1R activity would prevent 
pathological excitability and epilepsy susceptibility. On the other hand, activation of 
A2AR, could bypass the impairment of BDNF actions and exert potential benefic effects 
on cognition. 
 
Key words: Rett Syndrome, Adenosine, A1 receptor, A2A receptor, BDNF. 
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1. INTRODUCTION 
1.1 Rett Syndrome 
Rett Syndrome (RTT) is a rare neurodevelopmental disorder that occurs mainly 
in females and it is characterized by normal development up to the first year and a half 
of age, at which the main symptoms start to appear (Na and Monteggia, 2011). The 
manifestations of the disease are usually apraxia (the inability to execute learned 
purposeful movements), deceleration of head growth, compulsive hand movements, 
mental retardation. Rett patients can also display epilepsy, sleep disturbance, scoliosis, 
and an abnormal cardiac cycle that can result in sudden death (Zoghbi and Bear, 2012) 
 Rett syndrome is considered today to be the leading cause of severe 
intellectual disability in females, with a prevalence estimated of 1 in 10.000 females 
being clinically diagnosed (Na and Monteggia, 2011). 
 Patients can live into their sixth and seventh decades without evidence of 
further progression of disease, although some can develop parkinsonic features 
(Chahrour and Zoghbi (2007). 
 
1.1.1 The Origin 
The disorder was first described by the Austrian pediatrician Andreas Rett in 
1966. Even though the description of the disease was done in the 60’s, it was only in 
1999 that a major medical breakthrough was achieved when Amir Ruthie discovered 
that mutations on the MeCP2 gene (Methyl-CpG binding Protein 2) were the primary 
cause for Rett Syndrome (Amir et al., 1999). This discovery helped to understand why 
RTT is prevalent in females, since the MeCP2 gene is located on the X chromosome, 
and why females who are heterozygous for the mutated MeCP2 allele, are able to 
survive with this debilitating disorder (Na and Monteggia, 2011). Furthermore, it can 
clarify the fact that males that are hemizygous for MeCP2 mutations have a drastically 
shortened lifespan of approximately 2 years and typically develop congenital 
encephalopathy (Ravn et al., 2003; Villard et al., 2000). 
It is known that 99% of RTT occurrences are sporadic, caused either by 
missense, nonsense, insertions, deletions or splice site variations mutations all 
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throughout the gene (Na and Monteggia, 2011), even though there are some familial 
cases reported in which the disease was inherited through maternal lines (Van den 
Veyver and Zoghbi, 2001). While looking at the genotype-phenotype correlation, some 
groups report more severe phenotypes with truncating mutations compared to 
missense mutations, while others found the exact opposite, but overall, most studies 
did not detect an unequivocal genotype–phenotype correlation (Van den Veyver and 
Zoghbi, 2001). 
In spite of about 80% of the RTT cases being caused by mutations in the MeCP2 
gene located on Xq28, there were some RTT patients that had no mutations on this 
gene. Thus, it was proposed that at least one other locus would be responsible for RTT. 
Indeed, two groups of authors described cases of RTT-like phenotypes caused by 
truncating frameshift and missense mutations in the gene for cyclin-dependent kinase-
like 5 (CDKL5) (Matijevic et al., 2009). Even more, it was discovered that the FoxG1 
gene, forkhead box protein G1 gene, is responsible for the congenital variant of Rett 
Syndrome (Ariani et al., 2008) 
 
1.1.2 The MeCP2 gene 
Identification of the gene responsible for RTT was an essential precondition for 
understanding the mechanism involved in the development, genetic diagnosis, genetic 
counseling and, ultimately, for therapy of this debilitating disorder (Nan and Bird, 
2001). 
The MeCP2 gene has 4 exons and its protein is an abundant, ubiquitously 
expressed nuclear protein composed by 486 amino acids, most frequently encoded by 
a second, third and fourth exons (Figure 1) (Matijevic et al., 2009). The gene is highly 
conserved between species, not only in its coding region, but also in the 3’ and 5’ 
untranslated regions (UTR) (Van den Veyver and Zoghbi 2001).  
 
 
Figure 1 – The structure of MeCP2. (Adapted from (Matijevic et al., 2009) 
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The MeCP2 protein contains four functional domains: (1) a methyl-CpG-binding 
domain (MBD, 85 amino acids) which binds to 5-methyl cytosine with a high affinity; 
(2) a transcriptional repression domain (TRD, 104 amino acids) which interacts with 
histone deacetylase and transcriptional corepressor SIN 3A; (3) the nuclear localization 
signal which may be responsible for the transport of MeCP2 into the nucleus, and (4) 
the C-terminal segment which facilitates its binding to the nucleosome core (Matijevic 
et al., 2009). 
Epigenetic mechanisms, such as DNA methylation and histone tail modifications 
(e.g., acetylation at lysine residues, methylation at lysine or arginine residues, and 
phosphorylation at serine or threonine residues), can either activate or repress gene 
transcription (Na and Monteggia, 2011). MeCP2 was first identified as a transcriptional 
repressor that inhibits gene expression through the interpretation of two epigenetic 
markers: DNA methylation and histone acetylation (Na and Monteggia, 2011). 
When MeCP2 binds to the methylated CpG islands it recruits a complex 
containing histone deacetylases (HDAC1 and HDAC2) and the co-repressor Sin3A (Van 
den Veyver and Zoghbi, 2001). The tails of core histones in the nucleosomes are 
deacetylated by HDACs, which leads to compaction of heterochromatin, making it 
inaccessible to the transcriptional activators and components of the transcriptional 
machinery, resulting in stable repression of downstream genes (Figure 2) (Van den 
Veyver and Zoghbi, 2001). 
 
 
 
 
 
Figure 2 – MeCP2 function as a transcriptional repressor. (Adapted from (Chahrour et al., 2008)) 
 
As oppose to what has been believed, new evidence has proposed that MeCP2 
may also bind to active genes and work as a transcriptional activator (Chahrour et al., 
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2008; Skene et al., 2010; Yasui et al., 2007) . Even more, MeCP2 has also been shown 
to interact with RNA to influence alternative splicing (Young et al., 2005). 
Although the gene is ubiquitously expressed, its expression is high in brain and 
occurs with a temporal and spatial pattern that correlates with neuronal maturation 
(Mari et al., 2005). In addition, it was thought that in the brain MeCP2 is expressed 
only in neurons and not in non neuronal cells. However, MeCP2 is also expressed in 
non neuronal cells, presumably astrocytes, and not only in the nucleus but also in the 
cytosol (Matijevic et al., 2009). 
It is known that MeCP2 can silence certain genes, however, the MeCP2 target 
genes associated with RTT pathogenesis could not be found (Matijevic et al., 2009). 
Two groups of authors have discovered that MeCP2 regulates the expression of the 
gene encoding brain-derived neurotrophic factor (BDNF) which is essential for neural 
plasticity, learning and memory. This discovery revealed the role of MeCP2 in the 
control of neuronal activity-dependent gene regulation and suggested that the 
pathology of RTT may result from deregulation of this process (Matijevic et al., 2009). 
BDNF is one of the most studied neurotrophins, and being part of the growth factors 
family it is involved in several functions on the nervous system. Neurotrophins, such as 
BDNF, have a prominent role on the nervous system according as various functions 
that include regulation of axonal growth, modulation of synaptic activity, promotion of 
survival and regulation of neuronal death (Arevalo and Wu, 2006). These actions of 
BDNF are possible through the activation of a specific membrane receptor TrkB, 
Tropomyosin related kinase B, to which BDNF binds with high affinity, inducing 
receptor dimerization and autophosphorylation in tyrosine residues in the cytoplasmic 
domain. Alterations on the signaling mediated by neurotrophins are very often present 
in pathologies such as Parkinson’s and Alzheimer’s (Roux and Barker, 2002) and on 
MeCP2 mutant mice it was shown that levels of BDNF protein were decreased. 
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1.1.3 Consequences of the deregulation of MeCP2 gene 
After discovering that mutations on the MeCP2 gene caused RTT, many studies 
started to arise trying to discover which alterations would happen, that ultimately led 
to the disease. 
 RTT has been previously proposed as a disorder of synaptic formation since the 
MeCP2 dysfunction leads to abnormal brain development through maladjustment of 
neuronal gene expression to synaptic and other extra-cellular signals, mainly during 
the critical period of synaptic maturation (Kaufmann et al., 2005). 
Initial abnormal synaptic maturation leads to abnormal synaptic structure that, 
in turn, further intensifies the maturational disruption. The combination of 
anomalously configured synaptic circuits and continuous molecular deficiency 
ultimately determines the severity of the neurobehavioral phenotype beyond late 
childhood. Although these general principles appear to operate in several disorders, 
the challenge is to identify the features unique to each condition. For instance, in RTT, 
the neurotransmitter systems abnormalities secondary to early MeCP2 dysfunction, 
seems to play an important role in ‘setting the stage’ for a highly disrupted process of 
synaptic maturation. Significant variability in regional MeCP2 expression and increasing 
levels of this protein into adulthood are other examples of features to be considered, if 
neurobiologically-based interventions for RTT are to be developed (Kaufmann et al., 
2005).  
 One of the outcomes of the deregulation of the MeCP2 gene that has been 
found, is that not only results in classic forms of RTT, but can also lead to a range of 
related neuropsychiatric disorders. For example, patients diagnosed with Angelman 
syndrome (Watson et al., 2001), non-syndromic mental retardation (Miltenberger-
Miltenyi and Laccone, 2003), Prader–Willi syndrome (Samaco et al., 2004), and some 
forms of autism (Shibayama et al., 2004) have mutations in the MeCP2 gene that 
significantly reduce MeCP2 protein expression levels. These findings designate that the 
effects of MeCP2 mutations are not necessarily consistent, and that understanding the 
developmental trajectory of MeCP2 expression, and the coupling of developmental 
stage-specific expression with neuronal function, may provide important insight into 
the etiology of RTT and other MeCP2-associated disorders (Na and Monteggia, 2011). 
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Utilizing rodent models of RTT has substantially enhanced the general 
understanding of how MeCP2 mutations can lead to the observed phenotypes (Na and 
Monteggia, 2011). For instance, when using a mice model that has a constitutive 
deletion of MeCP2, they first displayed severe neurological symptoms that included 
uncoordinated gait, hindlimb clasping and irregular breathing, followed by a period of 
normal development (Guy et al., 2001). It is fairly common to see on those mice 
reduced brain size and smaller, more densely packed neurons in the hippocampus, 
cortex and cerebellum (Chen et al., 2001). 
Behavioral characterization of these conditional MeCP2 knockouts revealed 
phenotypes that are strikingly similar to RTT patients, with significant defects in motor 
learning, as well as increases in anxiety-like behavior, impairments in social interaction 
and altered learning and memory-related behaviors (Gemelli et al., 2006).  
 On the other hand, transgenic mice models that overexpress MeCP2 mimic 
many of the same behavioral phenotypes seen in RTT patients and in MeCP2 KO mice 
(Na and Monteggia, 2011). It has been shown that mice with elevated levels of MeCP2 
develop seizures and become hypoactive (Jiang et al., 2013). Mice that overexpress 
MeCP2 specifically in postmitotic neurons also display significant impairments in motor 
learning, as well as tremors and gait ataxia (Luikenhuis et al., 2004). These mice models 
clearly indicate that homeostatic regulation of MeCP2 is necessary for normal CNS 
functioning. Both the loss and overexpression of MeCP2 result in similar neurological 
deficits as those seen in patients with RTT, revealing a need for precise control over 
the amount of MeCP2 expression (Na and Monteggia, 2011). For example, MeCP2 
expression being abruptly restored in the brains of MeCP2 null mice before the onset 
of symptoms resulted in half of the animals experiencing neurological defects and 
subsequent death, and half avoiding development of any detectable symptoms (Guy et 
al., 2007), while gradual restoration of MeCP2 levels in MeCP2-deficient mice 
increased lifespan and reversed deficits in motor coordination and respiratory function 
in all animals. Recent advances might explain the previously reported phenotypic 
diversity (from mild to severe) (Mari et al., 2005). Recently, duplications of the Xq28 
region encompassing the MeCP2 gene were shown to segregate with mental 
retardation and progressive neurological symptoms in males (Van Esch et al., 2005). 
On the basis of these findings, it is possible to propose a model in which different 
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balancing of MeCP2 expression might be the cause of phenotypic diversity (Figure 3) 
(Mari et al., 2005). A gene-dosage-sensitive mechanism was confirmed in MeCP2 
transgenic mice, which develop a neurological phenotype of varying severity 
depending on the MeCP2 gene copy number (Collins et al., 2004). These results 
provide firm evidence that the central nervous system is extremely sensitive to MeCP2 
expression levels and that tight regulation of MeCP2 expression is crucial in pre- and 
postnatal brain development and function (Mari et al., 2005).  Although these 
preliminary results are encouraging and could lead to therapeutic options for this 
debilitating disorder, the importance of tight regulation of MeCP2 expression levels 
needs to be considered carefully in designing treatment strategies based on gene 
correction of RTT (Mari et al., 2005). 
 
 
 
 
Figure 3 – MeCP2 dosage balance. (Adapted from (Mari et al., 2005)) 
 As previously mentioned, patients with Rett syndrome display a normal period 
of development prior to symptom onset, and then undergo a period of regression, 
suggesting that MeCP2 may play a more functional role in early postnatal development 
rather than during embryonic periods (Na and Monteggia, 2011). 
 The study of the timing of MeCP2 expression in both humans and rodents has 
been very important in adding insight to this disorder. It is known that in the rodent 
CNS, the MeCP2 expression is first detected in the spinal cord and brainstem around 
day E12 (Jung et al., 2003; Shahbazian et al., 2002). Other brain areas such as 
thalamus, caudate putamen, cerebellum, hypothalamus, hippocampus and cortex are 
targets of MeCP2 expression at days E14-18 (Na and Monteggia, 2011). Over the 
course of cellular differentiation, amounts of MeCP2 protein increase such that, from 
early postnatal development into adulthood, MeCP2 is highly expressed in neurons 
throughout the brain (Shahbazian et al., 2002). In humans, neuronal maturation and 
synaptogenesis are key developmental processes that occur as early as embryonic 
weeks 12 and 20, respectively (Marsh et al., 2008). The loss of MeCP2 expression 
within this time window may be responsible for the observed decrease in neuronal and 
overall brain size in RTT patients. Disruptions in MeCP2 function might therefore 
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interfere with neuronal maturation and synaptogenesis, culminating in abnormal 
development of the CNS. 
The reduction in neuron size seen in MeCP2 null mice and RTT patients is only 
one of the observed effects resulting from the loss of MeCP2 function during CNS 
development (Na and Monteggia, 2011). It is very characteristic to find reductions in 
axonal and dendritic processes as well as decreased spine density in RTT patients 
(Armstrong, 2002). In female RTT patients, CA1 pyramidal neurons exhibit decreased 
dendritic spine density (Chapleau et al., 2009), and substantial decreases in dendritic 
arborization can be seen in the frontal, limbic, and motor cortices (Armstrong et al., 
1998). MeCP2-deficient neurons also have fewer dendritic spines and reduced 
arborization in the hippocampus and exhibit additional impairments in neuronal 
maturation in both the hippocampus and in the olfactory system (Palmer et al., 2008; 
Smrt et al., 2007; Zhou et al., 2006). The impacts on dendritic morphology seen with 
mutations in MeCP2 likely contribute to the cognitive impairments observed in RTT 
patients (Na and Monteggia, 2011). Thus, an obvious consequence of reduced 
dendritic complexity is an effect on synaptogenesis. The control of MeCP2 expression 
in hippocampal neurons leads to alterations in dendritic spines, the locations of 
excitatory synapses along dendrites (Chapleau et al., 2009). 
The learning deficits and reductions in dendritic arborization observed in mouse 
models of Rett syndrome suggest that MeCP2 plays a vital role in synapse function (Na 
and Monteggia, 2011). The changes found in neurotransmission suggest an overall 
shift in the ratio of excitation to inhibition. The direct functional consequences of this 
imbalance have not been identified as of yet. However, it is reasonable to hypothesize 
that changes in excitatory neurotransmission may reflect changes in action potential 
firing thresholds, ultimately resulting in significant changes in network activity (Na and 
Monteggia, 2011). 
 
1.1.4 Treatment strategies  
Although there is no current treatment for this disorder per se, but instead for 
the control of the major symptoms such as epilepsy, the finding that MeCP2 regulates 
a large number of genes suggests a need for therapeutic strategies that focus on 
restoring neuronal function rather than restoring the activity of individual gene 
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products affected by MeCP2 dysfunction (Chahrour et al., 2008). It might prove 
challenging to restore the level of each of these genes at the same time. Thus, an 
alternative approach will be to identify proteins or pathways that suppress MeCP2 
dysfunction phenotypes, or bypass MeCP2, and restore neuronal homeostasis 
(Chahrour et al., 2008). 
Grounded on the knowledge that MeCP2 could affect BDNF gene expression 
(Chen et al., 2003) and that BDNF levels are diminished in RTT (Chang et al., 2006), new 
strategic approaches were designed in order to increase BDNF levels and consequently 
its actions. However, the administration of drugs destined to exert its effects on the 
brain must have the capacity to cross the blood-brain barrier. Pharmacokinetic 
properties of BDNF unable its ability to reach the brain after a peripheral 
administration (Pardridge et al., 1994). Therefore, new concepts started to be 
considered involving the use of small molecules, which by penetrating the blood brain 
barrier might stimulate the synthesis and/or potentiate the effects of endogenous 
neurotrophins. One of those molecules is adenosine. Adenosine through the activation 
of a particular type of adenosine receptors, the A2A receptor (A2AR), can induce 
phosphorylation and consequent activation of TrkB receptors even in the absence of 
BDNF (Lee and Chao, 2001). Moreover, it is known that the activation of A2AR is a 
prerequisite essential to the facilitatory effects of BDNF upon synaptic transmission 
(Diogenes et al., 2004; Tebano et al., 2008), and plasticity (Fontinha et al., 2008).  
 
1.2 Adenosine 
Adenosine (Figure 4) is one of the most studied molecules. It is a purine 
ribonucleoside, which means it is formed when a purine (adenine) is covalently bound 
to a ribose (ribofuranose). 
Given the fact that adenosine is “omnipresent”, i.e., exists in every cell and it is 
released by all cells, including neurons and glial cells (Ribeiro et al., 2002), this 
substance plays an important role to maintain energy homeostasis in most organ 
systems including the brain (Newby et al., 1985).  
Among main bodily functions are regulation of seizure susceptibility – 
endogenous anticonvulsant actions (Boison, 2005), neuroprotection (Rebola et al., 
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2005), regulation of pain perception (Sadigh-Lindell et al., 2003), sleep induction 
(Porkka-Heiskanen et al., 2003), central respiratory control (Gourine, 2005), 
cardioprotection (Minamino and Kitakaze, 2002) and the regulation of heart rate, 
blood pressure (Blood et al., 2002), and body temperature (Gourine et al., 2002). 
 
 
 
 
 
Figure 4 – Adenosine chemical structure – Adenine (in the red 
square) and ribofuranose (in the blue square) bound by a C1’-N9 
glycosideic bond. (Adapted from Diogenes, M.J. PhD Thesis) 
 
 
 
1.2.1 Adenosine synthesis 
Intracellularly, adenosine can be formed by the action of the enzyme endo-5’-
nucleotidase on adenosine monophosphate (AMP) (Phillips and Newsholme, 1979) and 
by the hydrolysis of S adenosylhomocysteine (SAH) (Nagata et al., 1984) catalyzed by 
SAH hydrolase. The levels of endogenous adenosine are controlled by adenosine 
kinase (AK), which phosphorylates adenosine to produce AMP, and by adenosine 
deaminase (ADA), which catalyzes the formation of inosine (Figure 5). Extracellularly, 
adenosine can be formed by the action of the enzyme ecto-5’-nucleotidase on AMP 
resultant from cyclic AMP. 
Since adenosine is considered a neuromodulator instead of neurotransmitter 
due to not accumulating and releasing by synaptic vesicles, this molecule is released 
from the cytoplasm into extracellular space through nucleoside transporters (Ribeiro 
et al., 2002) as oppose as classical neurotransmitters. 
It is known that intracellular concentration of adenosine in basal conditions is 
about 100 nM (Meghji et al., 1992), and the extracellular concentration under the 
same circumstance can vary from 30 to 300 nM (Schulte and Fredholm, 2003). 
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Figure 5 – Pathways of adenosine production, metabolism and transport – Abbreviations are as follows:               
ADA – adenosine deaminase; AK – adenosine kinase; es – equilibrative-sensitive nucleoside transporters; ei – 
equilibrative-insensitive nucleoside transporters; SAH – S-adenosyl homocysteine. (Adapted from (Latini and 
Pedata, 2001)). 
 
 
1.2.2 Adenosine receptors 
Adenosine and its receptors are a subject that have been largely studied over 
the years, and currently, it is well accepted that there four different receptors to which 
adenosine can bind: A1, A2A, A2B and A3.  
  These receptors are classified as seven transmembrane domain G-protein-
coupled receptors and the original classification was based on the effect on adenosine 
binding to the receptor affecting the cyclic AMP (cAMP) levels in different tissues 
(Londos et al., 1980; van Calker et al., 1979). 
 The adenosine A1 receptor (A1R) are highly expressed in brain cortex, 
cerebellum, hippocampus, and the dorsal horn of spinal cord (Figure 6) (Fredholm et 
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al., 2001) and can be present in pre-, post- and non-synaptic sites. Since A1R are 
coupled to the Gi family of G-proteins, they have the capacity to stimulate K
+ channels, 
causing membrane hyperpolarization post-synaptically, and to reduce transient 
voltage dependent Ca2+ channels and inhibit cAMP formation (Figure 7) (Boison, 2010). 
When they are located pre-synaptically, they inhibit neurotransmitter release due to 
the binding of the Go domain (Dunwiddie and Haas, 1985). 
 The A2AR are highly expressed post-synaptically in the striatum-pallidal 
GABAergic neurons and olfactory bulb (Fredholm et al., 2001); they are also expressed 
in hippocampus and cortex (Figure 6) (Ribeiro et al., 2002) where they have a 
predominant pre-synaptic localization (Rebola et al., 2005). The majority of A2AR are 
coupled to stimulatory G-proteins (Gs), which consequently increase intracellular cAMP 
(Figure 7) and promote the release of cytokines, which may serve as part of an 
important feed-forward mechanism to locally control neuroinflammatory responses in 
the brain (Boison, 2010). The A2AR can also be found coupled to the Golf domain in the 
striatum (Corvol et al., 2001) which is associated with increased nerve activity and LTP 
(Long-Term Potentiation - a form of synaptic plasticity which is considered the 
neurophysiological basis for learning and memory) (Figure 7). 
 The A2B receptor is known to display low levels of expression in the brain (Dixon 
et al., 1996), although their expression is noted in astrocytes (van Calker et al., 1979). 
A2B receptors can couple to two different classes of G-proteins: Gq and Gs – the Gq 
regulates intracellular calcium and vesicular release, whereas Gs affects a variety of 
cAMP dependent signaling pathways (Figure 7) (Boison, 2010).  
 The A3 receptor has apparent intermediate levels of expression in the human 
cerebellum and hippocampus (Figure 6) and low levels in the rest of the brain 
(Fredholm et al., 2001). The affinity of this receptor for adenosine (Ki=6500 nM) is 
considerably lower than the adenosine affinity of A1 (Ki=70 nM) and A2A (Ki=150 nM) or 
even A2B (Ki=5100) receptors (Pagonopoulou et al., 2006). This receptor is usually 
coupled to inhibitory G-proteins such as Gi (Linden, 2001) which can promote MAP 
kinase (Mitogen-Activated Protein kinase) activation, a pathway associated with cell 
growth and survival (Figure 7) (Boison, 2010). 
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Figure 6 –Distribution of high affinity adenosine receptors (A1, A2A and human A3). High levels are 
indicated by larger font. (From (Ribeiro et al., 2002)).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Adenosine receptors, their coupling to G-proteins and some of the down-stream 
consequences of receptor activation. (From (Boison, 2010)).  
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1.2.3 Adenosine mediated actions: pathophysiological implications 
As previously mentioned, adenosine through the activations of its receptors has 
the capacity to modulate the release of several neurotransmitters and other 
neuromodulators. Moreover, adenosine has the ability to regulate the function of 
other receptors that affect several biological functions such as neuropeptide receptors, 
nicotinic autofacilitatory receptors, metabotropic glutamate receptors, NMDA 
receptors and neurotrophic receptors (see for review (Ribeiro and Sebastiao, 2010)). 
 The neuromodulation system of adenosine as been considered as a putative 
therapeutic target to manage brain disorders. This interest has been growing due to 
the recurrent observations showing that the extracellular levels of adenosine are 
modified upon brain damage (Gomes et al., 2011). This is likely a result from the 
increased use o ATP to attempt preserving cell viability, which ultimately leads to 
disproportionally higher formation of adenosine (Gomes et al., 2011). It is clear that 
the elucidation of the metabolic and cellular sources of extracellular adenosine is still 
not understood. Provided that adenosine is apparently involved in many functions that 
can play a role in the pathology of the nervous system, the modifications of 
extracellular levels of this molecule or the pharmacological or molecular manipulation 
of adenosine receptors may interfere with the action of other important molecules 
that regulate brain functions. And therefore, this could be relevant for future 
treatment of several diseases, through the activation or inhibition of adenosine 
receptors which may modulate certain pathways that could change the fate of these 
diseases. 
 The pharmacological manipulation of adenosine has for some years been 
suggested for the treatment of various health conditions (Ribeiro et al., 2002). 
One field of interest, where adenosine’s manipulation has been studied, is the 
regulation of sleep. It has been shown (Benington et al., 1995; Porkka-Heiskanen et al., 
1997) that adenosine functions as a natural sleep-promoting agent mostly through 
activation of A1 receptors (Figure 8). It was suggested that adenosine participates in 
resetting of the circadian clock by manipulation of behavioral states (Antle et al., 
2001). Thus, it emerges that there exists a potential role for adenosine-related 
compounds and of A1 receptor agonists as sleep promoters and adenosine receptor 
antagonists as arousal stimulators.  
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Regarding health conditions such as anxiety, it was demonstrated the utility of 
A1R agonists as anxiolytic compounds, suggesting that drugs that facilitate adenosine 
A1 receptor-mediated actions may be effective for the treatment of anxiety (Florio et 
al., 1998; Jain et al., 1995) (Figure 8). 
 In spite of the treatments available nowadays in form of antiepileptic drugs 
(AEDs), seizures persist in approximately 35% of patients; hence a strategy that 
prevents seizures in drug-resistant epilepsy would be an important therapeutic 
advance. In studies using a mouse model for drug-resistant mesial temporal lobe 
epilepsy, in which recurrent spontaneous seizure activity was induced by a single 
intrahippocampal injection of kainic acid, the administration of an A1R agonist led to 
the suppression of seizure activity (Gouder et al., 2003). Moreover, in vivo and in vitro 
studies were performed in models of epilepsy to evaluate the antiepileptic effects of 
AMP, the precursor of adenosine, and this molecule indeed inhibited excitatory 
neurotransmission by directly activating A1R and prolonged latency of convulsions 
(Muzzi et al., 2013) (Figure 8).  
  A decrease in levels and/or action of neurotrophic factors such as BDNF have 
been implicated in the pathophysiological mechanisms of many diseases of the 
nervous system, such as Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s 
disease, diabetic neuropathies, ALS, depression and even RTT, therefore making the 
use of the naturally occurring neurotrophic factors promising for treatment of these 
disorders (Sebastiao and Ribeiro, 2009). However, until now the pharmacological 
administration of neurotrophic factors in vivo has not been easy as these molecules 
are unable to cross the blood brain barrier, making invasive application strategies like 
intracerebroventricular infusion necessary (Sebastiao and Ribeiro, 2009). The evidence 
that adenosine A2AR trigger or facilitate actions of neurotrophins upon synaptic 
strength and neuronal survival opens a new therapeutic strategy, as there are A2AR 
agonists that cross the blood brain barrier, which can be explored as tools to 
potentiate neurotrophic actions in the brain (Sebastiao and Ribeiro, 2009). In 
summary, the neuromodulator adenosine, through A2AR activation, has profound 
influence upon the actions of neurotrophic factors and due to the role of neurotrophic 
factors upon neuronal survival, neuronal plasticity and neuronal differentiation, the 
adenosine-induced control of neurotrophic factors opens new windows of 
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adenosinergic influence on neuronal cells and novel therapeutic perspectives in 
neuronal dysfunction (Sebastiao and Ribeiro, 2009). 
Although adenosine receptor agonists have been pointed out to be promising 
in future therapies, these substances may have marked side effects in vivo, including 
bradycardia and hypotension ((Barraco et al., 1984); see also (Dunwiddie, 1999)). 
Therefore, it has been frequently suggested the use of other substances that indirectly 
modulate the levels of endogenous adenosine such as mioflazine which is an 
adenosine uptake inhibitor that was effective as a sleep enhancer (Hoppenbrouwers 
and Bussche, 1989). Besides the use of alternative substances to modulate the levels 
of adenosine, there are other therapies that have been suggested to avoid the 
systemic side effects of adenosine’s agonists, intervening focally, which are the 
adenosine augmentation therapies (AAT) (Boison, 2009). There are mainly three types 
of AAT: the silk-based brain implants, the encapsulated cells and stem cell-derived 
brain implants. Silk is biocompatible and biodegrades slowly and the delivery of doses 
of adenosine are predetermined and it was proven its therapeutic efficacy trough 
antiepileptogenic properties (Boison and Stewart, 2009). On the second approach, a 
suitable cell line is first genetically engineered to release a therapeutic compound, 
which in this case is adenosine, and then encapsulated in a semipermeable polymer 
membrane and transplanted locally into the host’s brain. Cell-encapsulation permits 
the exchange of oxygen, extracellular metabolites, and nutrients between the 
encapsulated cells and the host tissue and it shows anticonvulsant properties. Most 
importantly, the focal use of cell-based adenosine delivery did not cause receptor 
desensitization, nor was it accompanied by sedative side effects (Boison and Stewart, 
2009). The third type of AAT is stem cell-derived brain implants to secrete adenosine. 
Stem cell-derived brain implants can also be engineered to release therapeutically 
active molecules with the aim to provide therapeutic benefit by paracrine 
mechanisms. It is a combination of functional integration and paracrine drug delivery 
and has shown antiepileptogenic or disease-modifying properties (Boison and Stewart, 
2009). Although the effects of AAT have only been tested on epilepsy models (Figure 
9), these therapies could be promising in treating other pathologies where the levels of 
adenosine are pathologically altered. 
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Figure 8 – Possible therapeutic strategies using adenosine receptors. (Adapted from Diogenes, M.J. PhD Thesis) 
 
 
 
 
 
Figure 9 – Summary of adenosine augmentation therapies studies. (Adapted from (Boison and Stewart, 
2009)). 
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2. AIM 
RTT is a genetic disorder that originates severe intellectual disabilities besides 
other symptoms such as epilepsy. RTT is caused primarily by mutations in MeCP2 
gene. One of the most prominent genes under the control of MeCP2 is the BDNF 
gene. Therefore, in this pathology there is an impairment on BDNF signaling. Until 
now there is no pharmacological treatment available for RTT. The increase of BDNF 
signaling would be a great breakthrough, but has been hampered by the difficulty 
to administer BDNF so that it reaches the brain. Therefore, the use of molecules 
with the ability to potentiate BDNF actions has been pointed out as a promising 
possibility. The activation of A2AR is known to potentiate BDNF synaptic actions. On 
the other hand, A1R have been suggested to be important in the control of 
epilepsy, since they are inhibitory receptors. Therefore, adenosine may influence 
synaptic dysfunction in RTT through A1R activation, leading to epilepsy control, and 
through A2AR activation promoting potentiation of BDNF effects. However 
adenosine signalling was never evaluated in RTT either in humans or in animal 
models. Therefore, this project was designed to characterize adenosine mediated 
signalling in a well established RTT mice model, the MeCP2 knock out (KO) model.   
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3. METHODS 
3.1 Biological sample preparations 
3.1.1 Animals: 
All experiments were performed with adult (6-10 weeks old) Black six mice, in 
wild type and in MeCP2 Knock Out type (B6.129P2 (C)-Mecp2tm1.1Bird/J), handled 
according to the Portuguese law on Animal Care and European Union guidelines 
(86/609/EEC).  
The animals were housed in the local Animal House on a 12hours light/dark 
cycle and were provided food and water ad libitum. Care was taken so to reduce the 
number of used animals to the absolutely necessary. 
 
3.1.2 Hippocampus isolation and slice preparation: 
The animals were anesthetized with Isoflurane (in 1, 2-Propylenglycol 50% 
(v/v)) in an anesthesia chamber. After the first signs that indicate the anesthesia state, 
like the lack of a righting reflex and reduction in respiratory rate, the mice were 
sacrificed by decapitation. In order to obtain access to the brain, the skull was exposed 
by cutting the skin at the top of the head and then the brain was removed, and placed 
into ice-cold artificial cerebrospinal fluid (aCSF) (Krebs’ solution) containing (in mM): 
124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 1 MgSO4, 2 CaCl2, and 10 glucose, 
previously gassed with 95% O2 and 5% CO2, pH 7.4, as seen in Figure 10 (A). The brain 
was separated into two hemispheres through the midline and the hippocampus was 
isolated - Figure 10 (B) - always taking caution not to touch the hippocampus with the 
spatulas. Once the isolated, the hippocampus was is cut perpendicularly to the long 
axis into slices (400 μm thick) with a McIlwain tissue chopper - Figure 10 (C) - and 
allowed to recover, for at least one hour, in a resting chamber - Figure 10 (D) - in Krebs’ 
solution at room temperature. 
 
 
 
 
Figure 10 – Hippocampal slices preparation – (A) Brain removed. (B) Hippocampus isolation. (C) McIlwain tissue 
chopper. (D) Resting chamber. (Adapted from Pinho, J.S. Master Thesis)  
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3.1.3 Cortical homogenates: 
Protein extracts for western blot analysis were prepared from snap-frozen 
cortex and disrupted with a Teflon pestle in a 50 mM sucrose-Tris pH 7.6 and 
supplemented with protease inhibitors (Complete; Roche Applied Science, Mannheim, 
Germany). The protein content in the supernatants was determined using a 
commercial Bradford assay (Sigma, MO, United States of America). 
 
3.1.4 RNA extraction and cDNA synthesis: 
Total RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen) from 
cortex tissue, according to the manufacturer’s instructions. RNA concentration and 
purity were evaluated by spectrometry on the basis of optical density (OD) 
measurements at 260 and 280 nm.  
cDNA synthesis was performed in a 20 µl reaction mixture. A 4.3 µg total RNA 
was mixed with 1 µl random primer hexamer (Amersham) and 1 µl each of dATP, dTTP, 
dCTP, dGTP (each 10 mM) and incubated for 5 min at 65ºC. After cooling for 2 min at 
4ºC, the solution was mixed with 4 µl of 25 mM MgCl2, 2 µl of 10X RT Buffer ,2 µl of 
0.1M DTT, 0.5 µl SuperScript II Reverse Transcriptase (200 U; Invitrogen Life 
Technologies). The reaction was performed for 50 min at 42ºC and terminated by 15 
min incubation at 70ºC. Parallel reactions for each RNA sample were run in the 
absence of SuperScript II to assess the degree of any genomic DNA contamination. 
Completed RT reactions were stored at −20 ◦C until use. 
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3.2 Techniques  
 
3.2.1 Western Blot Analysis: 
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was 
used to evaluate the levels of A2AR. Total proteins (200 µg) were separated on 10% 
SDS-polyacrylamide electrophoresis gels and blotted onto a polyvinylidene fluoride 
membrane according to the standard procedures. The blots were probed overnight at 
4ºC with the monoclonal mouse anti-A2A in 3% BSA (Bovine Serum Albumin). After 
washing (3 x 5 min in TBST [10 mM Tris, 150 mM NaCl, 0,05% Tween 20 in H2O]), blots 
were then incubated with secondary antibodies conjugated with horseradish 
peroxidase and bands were visualized with a commercial enhanced 
chemiluminescence detection method (ECL) kit (PerkinElmer Life Sciences, MA, United 
States of America). Values were normalized to the α-Tubulin (loading control) and the 
relative intensities were normalized to WT (set as 1). Densitometry of the bands was 
performed using the Image J processing software (NIH, MD, United States of America). 
 
3.2.2 Extracellular Electrophysiological Recordings: 
Posteriorly of functional and energetic recovery, slices were transferred to a 
recording chamber for submerged slices, and continuously superfused at 3ml/min with 
bathing solution gassed with 5% CO2 and 95% O2 at 32ºC (Figure 11). The drugs were 
added to this superfusion solution for experiments. 
Recordings were obtained with an Axoclamp 2B amplifier and digitized (Axon 
Instruments, Foster City, CA). Individual responses were monitored, and averages of 
eight consecutive responses were continuously stored on a personal computer with 
the LTP program (Anderson and Collingridge, 2001). 
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Figure 11 – Setup for extracellular microelectrophysiology recordings. 1- Reference electrode.                                  
2- Stimulation electrode. 3- Recording electrode. 4- Temperature sensor. (Adapted from Diogenes, M.J. 
PhD Thesis). 
 
Field excitatory post-synaptic potentials (fEPSPs) were recorded (Figure 12 -B) 
through an extracellular microelectrode (4 M NaCl, 2–6 MW resistance) placed in the 
stratum radiatum of the CA1 area (Figure 12 - A). Stimulation (rectangular 0.1 ms 
pulses, once every 15 seconds) was delivered through a concentric electrode placed on 
the Schaffer collateral-commissural fibers, in the stratum radiatum near the CA3–CA1 
border. The intensity of stimulus (80–200 μA) was initially adjusted to obtain a large 
fEPSP slope with a minimum population spike contamination. Alteration on synaptic 
transmission was evaluated as the % change in the average slope of the fEPSP in 
relation to the average slope of the fEPSP measured during the 10 minutes that 
preceded the addition of drugs as previously described (Diogenes et al., 2004). 
 
 
 
 
 
 
Figure 12 – Extracellular recordings in hippocampal slices – (A) Representation of the stimulation of one 
pathway in a hippocampal slice to record field excitatory postsynaptic potentials (fEPSPs). (B) Traces 
obtained after stimulation composed of stimulus artifact (1), followed by the presynaptic volley (2) and 
the fEPSP (3).   (Adapted from Diogenes, M.J. PhD Thesis). 
3.2.2.1 Input-output curves: 
Input-output curves were performed to evaluate the basal synaptic 
transmission. After obtaining a stable baseline for at least 10 min, the stimulus 
delivered to the slice was decreased until no fEPSPs was elicited. The stimulus was 
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then successively increased by 20 μA steps. For each stimulation, data from three 
consecutive averaged fEPSP (each average fEPSP is the computerized mean of six 
individual fEPSP) were stored. The range of stimulation was from 60 μA until 340 μA. 
The input-output curve was plotted as the relationship of the fEPSP slope vs stimulus 
intensity, which provides a measure of synaptic efficiency. 
 
3.2.3 Radioligand Binding Experiments: 
 [3H]DPCPX binding studies were performed in cortical brain homogenates (40-
80 µg protein per assay) obtained from each different mouse group, [3H]DPCPX  
binding was carried out in an incubation solution containing 50 mM Tris-HCl buffer and 
10 mM MgCl2 (pH 7.4) and 4 U/ml ADA for 120 min at room temperature, in a final 
volume of 200 µl. Specific binding was calculated by subtraction of the nonspecific 
binding, defined in the presence of 2 µM XAC. The reaction was stopped by addition of 
cold incubation buffer and vacuum filtration through glass fiber filters (FilterMAT for 
receptor binding, Skatron Instruments, Lier, Norway) using a semiautomatic cell 
harvester from Skatron Instruments. The samples were transferred to scintillation vials 
and radioactivity was measured by a liquid scintillation analyzer (Tri Carb 2900TR, 
Perkin-Elmer, IL). Membrane protein content was quantified with the Bio-Rad protein 
assay according to Bradford (Bradford, 1976). 
 
3.2.4 Quantative PCR: 
qPCR for mRNA was done using Power SYBR® Green PCR Master Mix (Life 
Technologies), the pre amplified cDNA was used as the template for the real-time PCR 
run Rotor Gene 6000 (Corbett Life Science), according to the manufacturer´s 
recommendations. Negative Control PCR samples were run with no template. Fold-
changes were calculated using Cq method and normalized to the expression PPIA 
peptidylprolyl isomerase A (cyclophilin A) and Ribosomal protein L13A with Rotor-
Gene Series Software 1.7 (Corbett Life Science). Data normalized according to the 
following formula: Cq = Cq (target gene) – Cq (reference gene). 
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3.3 Pharmacological tools: 
Table 1 – Drugs and respective designation and function used in Electrophysiology and Binding experiments 
Abbreviation Designation Function Supplier 
 
ADA 
 
Adenosine deaminase (EC 
3.5.4.4) 
Adenosine 
deamination 
promoting 
enzyme 
Roche 
Diagnostics 
Corporation 
(Germany) 
 
CPA 
 
N6-Cyclopentyladenosine 
Adenosine A1 
receptor agonist 
 
Tocris (Bristol, 
UK) 
 
[
3
H]DPCPX 
1,3-[
3
H]-dipropyl-8-
cyclopentylxanthine 
Tritiated 
adenosine A1  
receptor 
antagonist 
American 
Radiolabeled 
Chemicals, Inc. 
(ST Luis, USA) 
 
DPCPX 
1,3-Dipropyl-8- 
cyclopentylxanthine 
Adenosine A1 
receptor 
antagonist 
 
Tocris (Bistol, UK) 
 
 
XAC 
 
8-{4-[(2- aminoethyl)amino]- 
Carbonylmethyloxy 
phenyl}xanthine 
 
 
 
Adenosine 
receptor 
antagonist 
 
 
RBI (Natick, MA, 
USA) 
  
*Aliquots of stock solutions were kept frozen at –20º C until used.  
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3.4 Antibodies: 
Table 2 - Primary and secondary antibodies and related conditions used in the Western blot experiments for 
individual proteins 
Protein 
Protein 
loading (µg) 
Resolving gel 
% 
Primary 
antibody 
Dilution 
Secondary 
Antibody 
Dilution 
A2AR 200 10 
 
Upstate 
(05-717) 
 
1:2000 
Anti-mouse 
 
1:5000 
α-Tubulin 200 10 
Abcam 
(ab4074) 
1:5000 Anti-rabbit 1:10000 
 
3.5 Primers: 
Table 3 – Primers and related conditions in the qPCR experiments for individual genes 
Primer 
symbol 
Gene Organism Forward Primer Reverse Primer 
Amplicon 
Size 
CypA * 
PPIA 
peptidylprolyl 
isomerase A 
(cyclophilin A) 
– Reference 
Gene 
mouse 
TAT CTG CAC TGC CAA GAC 
TGA GTG 
CTT CTT GCT GGT CTT GCC ATT CC 125bp 
Rpl13A 
* 
Ribosomal 
protein L13A – 
Reference 
Gene 
mouse 
GGA TCC CTC CAC CCT ATG 
ACA 
CTG GTA CTT CCA CCC GAC CTC 130bp 
A2A * 
Adenosine 
Receptor A2A 
mouse ATTCCACTCCGGTACAATGG AGTTGTTCCAGCCCAGCAT 113 bp 
A1 * 
Adenosine 
Receptor A1 
mouse TCGGCTGGCTACCACCCCTTG CCAGCACCCAAGGTCACACCAAAGC 155bp 
 
*All stocks are at 100µM and working solutions are at 5µM (Invitrogen). 
 
3.6 Data Analysis: 
 The values presented are mean ± SEM of n number of independent 
experiments. The significance of differences between the means of 2 conditions was 
evaluated by Student’s t-test. Values of P<0.05 were considered to represent 
statistically significant differences. 
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A1 A2 
4. RESULTS 
 
4.1 Extracellular levels of adenosine might be impaired in 
MeCP2 KO animals  
 
In a first step, we studied the extracellular adenosine levels by evaluating the 
disinhibition of synaptic transmission caused by the antagonism of A1R, as previously 
described (Diogenes et al., 2014). It is postulated that higher levels of adenosine can 
cause more prominent tonic A1R-mediated inhibition, and as a result, a higher 
facilitatory action of A1R antagonists should be visible (Diogenes et al., 2014). 
Accordingly, we compared the effect of the selective A1R antagonist, DPCPX, at the 
hippocampus at a supramaximal concentration (50 nM, Ki value for DPCPX at the 
hippocampus ~ 0.5 nM; (Sebastiao et al., 1990)) on synaptic transmission in 
hippocampal slices taken from WT and MeCP2-KO animals. In hippocampal slices taken 
from WT mice, DPCPX (50 nM) increased the slope of fEPSP to 45.30 ± 10.12 % (n=4, 
Figure 13 - A1-3), while in slices from MeCP2-KO mice, induced a lower, increase in 
fEPSPs (27.20 ± 4.524%, n=8). Therefore, a lowest disinhibition of synaptic transmission 
caused by DPCPX was observed in MeCP2-KO mice, whereas a greatest disinhibition 
was found in WT mice. These data show that the WT mice have greater A1 inhibitory 
tone than MeCP2 KO mice pointing to lower level of extracellular adenosine. 
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Figure 13 – Changes in fEPSP induced by DPCPX – A1 shows the averaged time courses of changes in fEPSP slope 
induced by application of DPCPX (50 nM) in slices taken from WT (black symbols, n= 4) and KO (blue symbols, n=8) 
animals. The ordinates represent normalized fEPSP slopes, where 0% corresponds to the averaged slopes recorded 
for 10 min before DPCPX application and the abscissa represents the time of every recording. Panel A2 shows the 
comparison of the averaged effects of DPCPX in the different genotypes. Panel A3 shows averaged fEPSPs obtained 
in a representative experiment in A1; each trace is the average of eight consecutive responses obtained 
immediately before (1) and during (2) DPCPX application both in WT (left panel) and KO animals (right panel), and is 
composed of the stimulus artifact, followed by the presynaptic volley and the fEPSP.  All values are mean ± standard 
error of mean (SEM).  
 
To corroborate this hypothesis we compared the effect of the selective A1R 
agonist, CPA, at the hippocampus at 3 different concentrations (3 nM, 10 nM, 30 nM) 
on synaptic transmission in hippocampal slices taken from WT and MeCP2-KO mice. 
Higher levels of endogenous adenosine can cause more prominent tonic A1R-mediated 
inhibition, and as a result, a lower inhibitory action of A1R agonists should be visible. 
The data obtained show an increased inhibitory action of A1R agonist (CPA) in KO when 
compared to WT experiments. In detail, in hippocampal slices taken from both WT and 
KO mice, CPA induced a concentration dependent decrease of synaptic transmission 
which became significantly different for the highest used concentration of CPA (30 nM) 
(fEPSPWT: 31.40 ± 5.878%, n=7 vs fEPSPKO: 52.35 ± 6.530%, n=7, P<0.05, Figure 14 - A1-
3).  
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Figure 14 - Changes in fEPSP induced by CPA – A1 shows the averaged time courses of changes in fEPSP 
slope induced by application of three different concentrations of CPA (3nM, 10nM, 30nM) in slices taken from WT 
(black symbols, n= 7) and KO (blue symbols, n=7) animals. The ordinates represent normalized fEPSP slopes, where 
0% corresponds to the averaged slopes recorded for 10 min before CPA application and the abscissa represents the 
time of every recording. Panel A2 shows the comparison of the averaged effects of different concentrations of CPA 
in the different genotypes. Panel A3 shows averaged fEPSPs obtained in a representative experiment in A1; each 
trace is the average of eight consecutive responses obtained immediately before (1) and during (2) CPA 30 nM 
application in both WT (left panel) and KO animals (right panel), and is composed of the stimulus artifact, followed 
by the presynaptic volley and the fEPSP. All values are mean ± standard error of mean (SEM). *P<0.05 (Student’s t-
test). 
 
Furthermore, to evaluate whether A1R expression and levels were affected, 
quantitative PCR and binding assays were preformed as described previously and in 
methods section. As shown in Figure 15 - A1, qPCR revealed no significant changes in 
cortical mRNA levels for A1R between WT and KO animals. The existence of 
commercially available tritiated ligands for A1R allowed receptor binding assays, which 
are frequently preferred for quantitative analysis of receptors. The A1R antagonist 
[3H]DPCPX was used as ligand for A1R. Figure 15 - A2 shows the saturation isotherms 
for the binding of [3H]DPCPX to cortical homogenates taken from the same brain as 
those used in extracellular electrophysiological recordings. It is evident that the 
specific [3HDPCPX binding is higher in MeCP2-KO animals than in WT mice, the 
difference being more pronounced for higher ligand concentrations. The Bmax values 
obtained by nonlinear regression analysis were 239 ± 24.57 fmol mg/protein (n=5) for 
the MeCP2-KO mice, and 127.8 ± 17.04 fmol mg/protein (n=5) for the wild type 
animals (P< 0.05). No significant differences in the Kd values were found (MeCP2-KO 
mice: 4.101 ±1.452 nM, n=5; WT mice: 6.748 ± 2.678 nM, n=5, P>0.05). This data show 
an increase in A1R levels in KO animals. Taken all together, this characterization 
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strongly favors the hypothesis of a decreased extracellular adenosine levels in KO 
animals with a compensatory increase on A1R protein levels.    
 
 
 
 
 
 
Figure 15 – A1R levels and expression – A1 histogram represents relative qPCR data showing mRNA levels of A1R 
(n=5) present in cortical samples from WT (black bars) and KO (blue bars) animals. PPIA peptidylprolyl isomerase A 
(cyclophilin A) and Ribosomal protein L13A were used as an internal loading control. In A2 are shown saturation 
isotherms for the binding of the selective A1R receptor antagonist [
3
H]DPCPX to the cortical homogenates of WT 
(black symbols, n=5) and KO (blue symbols, n=5) animals. All values are mean ± standard error of mean (SEM) ; 
#P<0.05 (F test). 
4.2 Levels of A2AR are increased in MeCP2 KO animals  
 
Given the changes detected on A1R levels, in this animal model, we also 
evaluated whether changes in cortical A2AR levels and expression could be present. 
Indeed, as seen in Figure 16 - B, it seems fairly evident that the levels of expression of 
A2AR mRNA levels are higher in KO animals (2.123 ± 0.3338, n=4) than WT mice (1.000 
± 0.2855, n=5, P<0.05). One the other hand, while evaluating A2AR levels by western 
blot, in four brain samples, reveals no significant changes in cortical protein levels for 
A2AR between WT and KO animals (n=4, Figure 16 - A1,2, P>0.05).    
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Figure 16 – A2AR levels and expression –  In A1 are shown the averaged of A2AR receptors density evaluated in four 
cortical brain samples by western blot analysis taken from WT (black bars) and KO (blue bars). A2 shows 
representative western blot using an antibody which recognizes A2AR receptors (~45 KDa). α-tubulin (~50 KDa) was 
used as loading control. The values obtained for WT samples were considered as 1.B histogram represents relative 
qPCR data showing mRNA levels of A2AR present in cortical samples from WT (black bars, n=5) and KO (blue bars, 
n=4) animals. PPIA peptidylprolyl isomerase A (cyclophilin A) and Ribosomal protein L13A were used as an internal 
loading control. All values are mean ± standard error of mean (SEM); *P<0.05 (Student’s t-test).  
 
Given the fact that we found so many alterations on signaling mediated by 
adenosine, and knowing that adenosine influences synaptic transmission mainly 
through A1R activation, we performed I/O curves to evaluate if basal synaptic 
transmission was altered. Indeed, the hippocampal slices taken from KO animals 
displayed higher Emax values when compared with WT animals (EmaxWT= 0.9901 ± 
0.04626, n= 4; EmaxKO= 1.781 ± 0.2129, n=4, P<0.05, F test; Figure 17). Therefore, 
suggesting that RTT animals have actually higher synaptic activity that can be 
explained, in part, by the decreased adenosinergic tonus. 
 
 
 
 
 
 
 
Figure 17 – I/O curve – Figure shows the input/output (I/O) curves corresponding to responses generated by 
various stimulation intensities (60–340 µA) in WT slices (black) and KO slices (blue). All values are mean ± standard 
error of mean (SEM); #P<0.05 (F test) 
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5. DISCUSSION AND FUTURE PERSPECTIVES 
 
The predominant influence of adenosine in the hippocampus is inhibition of 
synaptic transmission through A1R activation (Sebastiao et al., 1990). It is, therefore, 
possible to assess changes in extracellular adenosine levels in the vicinity of the 
synapses by evaluating the disinhibition of synaptic transmission caused by 
antagonism of the A1R. The assumption is that higher levels of adenosine cause more 
pronounced tonic A1R-mediated inhibition, and therefore, a higher facilitatory action 
of A1R antagonists should occur. On the other hand, if there is decreased tonic A1R 
activation, the A1R agonists would induce a higher decrease on synaptic transmission. 
We found that MeCP2 KO animals, in spite of having increased levels of A1R, 
revealed by binding assays, they have a lower adenosinergic inhibitory tone in their 
hippocampus as demonstrated by: 1) the lower degree of disinhibition of synaptic 
transmission by A1R blockade; by the 2) highest degree of inhibition of synaptic 
transmission by A1R activation and by 3) the highest synaptic activity revealed by I/O 
curves in MeCP2 KO animals. Interestingly, mRNA levels for A1R are not significantly 
affected in MeCP2 KO animals. This discrepancy between mRNA and protein levels was 
not evaluated in the present work and awaits future clarification. Interestingly, the 
impairment on A1R inhibitory tone by adenosine can also contribute for the epileptic 
susceptibility in RTT. Activation of the A1R provide immediate antiseizure effects 
through (1) the presynaptic inhibition of glutamate release, and (2) the stabilization of 
the postsynaptic membrane potential (Dunwiddie and Masino, 2001). Adenosine is an 
endogenous homeostatic regulator of network activity (Boison et al., 2011; Diogenes 
et al., 2014), and adenosine deficiency has been identified as a pathologic hallmark of 
the epileptic brain (Aronica et al., 2013). Consequently, adenosine augmentation 
therapies constitute an effective strategy to suppress induced and spontaneous 
seizures, even those that are refractory to conventional antiepileptic drugs (Boison, 
2009, 2013). Mouse models of epileptogenesis suggest a sequence of events leading to 
deregulated expression of AK and finally reduced adenosine. In addition, transgenic 
mice overexpressing AK display increased sensitivity to brain injury and seizures. 
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Moreover, inhibition of AK prevents seizures in a mouse model of pharmacoresistant 
epilepsy (Boison, 2013). 
Given the lower extracellular adenosine levels present in KO animals also A2AR 
are certainly affected and consequently its signaling pathways. Our results favor an 
increase in A2AR mRNA expression however the protein quantification reveals no 
difference when comparing the two genotypes. This discrepancy needs to be clarified 
in the future through Binding Assays which is a technique with more reliable, to 
quantify receptors, than Western Blot Analysis.  
The molecular experiences made on this project were done in cortex samples 
but in the future it will be necessary to perform the same experiences on hippocampal 
samples to confirm the presence of the same profile. Since we only used symptomatic 
animals on this work, it would be interesting in the future to characterize the 
asymptomatic mice (at 3 weeks of age), and instead of developing possible therapeutic 
strategies after the onset of the disease, it would be a rather compelling approach 
trying to understand which mechanisms change that lead to the trigger of the disorder 
and discover a way to prevent that. It is also important to mention that besides our 
characterization of adenosine receptors in this model, there are also in progress 
molecular experiences with autopsy samples from girls with RTT versus control to 
confirm our hypothesis as well as in human as in iPS (Induced pluripotent stem cells).   
As previously mentioned, BDNF plays important role in neuronal survival and 
synaptic plasticity. Most of these actions have been seen to occur through BDNF’s 
specific tyrosine kinase receptor (TrkB) and are dependent on A2AR activation 
(Diogenes et al., 2004). Since BDNF and TrkB receptors levels and the adenosinergic 
tonus are altered in symptomatic stages of the RTT model, we postulate that the 
activation of A2AR, together with the exogenous administration of BDNF, could rescue 
BDNF actions upon LTP.  
These findings open up a therapeutic window in RTT, through the modulation 
of adenosine signaling. Further studies are needed to consolidate our knowledge 
about adenosine dysfunction in RTT, such as the functional characterization of A2AR by 
Electrophysiological studies. However, in view of the present results, increasing 
adenosine tonus or acting directly at the specific receptors could have a potential 
beneficial role in this disorder. Increasing A1R activity would prevent pathological 
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excitability and epilepsy susceptibility. On the other hand, activation of A2AR, could 
bypass the impairment of TrkB signaling, restoring BDNF actions upon LTP, with 
potential benefic effects on cognition. Combining BDNF administration with increased 
adenosine availability or direct activation of A2AR could be beneficial for cognitive 
impairment in RTT. 
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6. CONCLUSION 
In conclusion, we found that the adenosinergic system is compromised in this RTT 
model (Figure 18), according to our results, in favor of a reduction of inhibitory 
adenosinergic tonus and also of an impaired activation of A2AR. Since evidence 
suggests that BDNF and TrkB receptors levels are impaired in RTT models, BDNF 
signaling modulation, through A2AR activation, potentiating TrkB signaling pathway, 
could be a promising therapeutic approach for RTT. 
Figure18 – Deregulation of endogenous adenosine tone in MeCP2 KO animals – Hippocampal extracellular tone of 
adenosine, exerts upstream control over 2 major adenosine-dependent pathways: (1) A2AR-dependent promotion of 
BDNF signaling, and (2) A1R-dependent inhibition of synaptic transmission. In WT animals (left panel), normal levels 
of adenosine facilitate BDNF actions by TrkB-FL receptors activation upon synaptic plasticity through the activation 
of A2AR and inhibit synaptic transmission through A1R. In MeCP2 KO animals (right panel), decreased levels of BDNF 
and TrkB-FL receptors observed and also a possible decrease on adenosine levels, which in turn could induce an 
upregulation on adenosine receptors. The reduced activation of adenosine receptors (dashed arrows) in particular 
A2AR implies an aggravation on the BDNF signaling impairment. These findings reinforce BDNF signaling pathways  
as possible pharmacological targets but importantly add adenosine and its receptors as new promising 
pharmacological targets (orange asterisks). 
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